Aortech chiefs keep share deals in-house
A round-up of the biggest director buys today so far.
Bosses at loss-making medical devices company Aortech International have been dealing shares among themselves, it emerged today.
Non-executive directors Edward McDaid and Gordon Wright both sold 30,000 shares at 130p each, which were snapped up by chief executive Frank Maguire and chairman Jon Pither.
Maguire's purchase of 79,850 shares in total, worth nearly £104,000, takes his stake to just over 81,000, or 1.7% of the company. Pither's acquisition of 15,050 shares opens his account.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Stuart Rollason, another non-exec, bought 3,000 shares at the same price, boosting his holding to almost 12,000.
In December, Aortech reported a loss before tax of £1.2m for the six months ended 30 September 2008, out from £759,000 the year before.
Its key product, Elast-Eon, is a long-term implantable copolymer, similar to silicon, which is used to make devices such as heart valves.
Top Director Buys
Value: £103,805
Value: £33,821
Value: £30,000
Value: £19,565
Value: £11,760
Value: £17,000
Top Director Sells
Value: £176,610
Value: £121,605
Value: £80,052
Value: £58,102
Value: £39,000
Value: £39,000
Value: £30,000
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Ofgem proposes new energy tariffs with low or no standing changes
Standing charges have invited public backlash as households battle high energy bills
By Katie Williams Published
-
Google shares bounce on Gemini 2.0 launch
Google has launched the latest version of its Gemini AI platform, and markets have responded positively. Is it time to buy Google shares?
By Dan McEvoy Published